SEPHguarding acute myeloid leukemia

Malini Gupta; Britta Will

doi:10.1016/j.stem.2022.02.007

SEPHguarding acute myeloid leukemia

Malini Gupta, Britta Will

Oncology

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this issue of Cell Stem Cell, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as an opportunity for targeted mitigation of malignant cell growth in AML.

Original language	English (US)
Pages (from-to)	350-352
Number of pages	3
Journal	Cell Stem Cell
Volume	29
Issue number	3
DOIs	https://doi.org/10.1016/j.stem.2022.02.007
State	Published - Mar 3 2022

ASJC Scopus subject areas

Molecular Medicine
Genetics
Cell Biology

Access to Document

10.1016/j.stem.2022.02.007

Cite this

@article{9fe5998863844765aabc43ae58a1816d,

title = "SEPHguarding acute myeloid leukemia",

abstract = "Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this issue of Cell Stem Cell, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as an opportunity for targeted mitigation of malignant cell growth in AML.",

author = "Malini Gupta and Britta Will",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = mar,

day = "3",

doi = "10.1016/j.stem.2022.02.007",

language = "English (US)",

volume = "29",

pages = "350--352",

journal = "Cell Stem Cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - SEPHguarding acute myeloid leukemia

AU - Gupta, Malini

AU - Will, Britta

PY - 2022/3/3

Y1 - 2022/3/3

N2 - Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this issue of Cell Stem Cell, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as an opportunity for targeted mitigation of malignant cell growth in AML.

AB - Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this issue of Cell Stem Cell, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as an opportunity for targeted mitigation of malignant cell growth in AML.

UR - http://www.scopus.com/inward/record.url?scp=85125265084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125265084&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2022.02.007

DO - 10.1016/j.stem.2022.02.007

M3 - Comment/debate

C2 - 35245465

AN - SCOPUS:85125265084

SN - 1934-5909

VL - 29

SP - 350

EP - 352

JO - Cell Stem Cell

JF - Cell Stem Cell

IS - 3

ER -

SEPHguarding acute myeloid leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this